Shares of PureTech Health plc (LON:PRTC) hit a new 52-week high on Wednesday . The company traded as high as GBX 189.50 ($2.48) and last traded at GBX 181.75 ($2.37), with a volume of 160682 shares traded. The stock had previously closed at GBX 180 ($2.35).
PRTC has been the topic of several analyst reports. Peel Hunt reaffirmed a “buy” rating on shares of PureTech Health in a research note on Monday, March 18th. Liberum Capital restated a “buy” rating on shares of PureTech Health in a research report on Monday, March 18th. Finally, Jefferies Financial Group restated a “buy” rating and issued a GBX 255 ($3.33) price target on shares of PureTech Health in a research report on Thursday, March 7th.
The company has a debt-to-equity ratio of 5.73, a current ratio of 0.97 and a quick ratio of 0.94. The stock has a market capitalization of $532.56 million and a PE ratio of 7.04.
ILLEGAL ACTIVITY WARNING: This piece was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2019/04/17/puretech-health-prtc-reaches-new-1-year-high-at-189-50.html.
PureTech Health Company Profile (LON:PRTC)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Recommended Story: Analyzing a company’s cash flow statement
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.